MerckVaccines.com

Product Features

Hib Antibody Response

List of Benefits

Prescribing Information

Storage and Handling

Proper Handling Demo

Select Safety Information

ACIP Recommendations

Disease Information

Haemophilus Influenzae type b (Hib)

Hepatitis B

Complimentary Resources

Select Another Product

The Hib component of COMVAX elicits a higher Hib antibody
response after 2 doses.^b,1

	Adapted from American Academy of Pediatrics (AAP), 1993.¹ Reproduced with permission from Pediatrics, Vol. 92, p a481. Copyright © 1993 by the AAP.
b	Compared to: HibTITER (a registered trademark of Wyeth Pharmaceuticals Inc.), ActHIB (a registered trademark of Sanofi Pasteur Pharmaceuticals SA), and OmniHIB (a registered trademark of GlaxoSmithKline Biologicals S.A.).
e	While the anti-PRP level associated with protection using conjugated vaccines has not yet been determined, the level of anti-PRP associated with protection in studies using bacterial polysaccharide immune globulin or nonconjugated PRP vaccines ranged from >0.15 mcg/mL to >1.0 mcg/mL.

COMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born to HBsAg-negative mothers. COMVAX should be administered at 2, 4, and 12 to 15 months of age. COMVAX should not be administered to any infant before the age of 6 weeks.

Select safety information

COMVAX is contraindicated in patients with hypersensitivity to yeast or any component of the vaccine. Persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

As with other vaccines, COMVAX may not induce protective antibody levels immediately following vaccination and may not result in a protective antibody response in all individuals given the vaccine.

In clinical trials, the most common nonserious adverse experiences observed in children receiving COMVAX included injection-site reactions, somnolence, irritability, crying, and fever (>101° F); for a listing of adverse reactions, please read the Prescribing Information.

Before administering COMVAX, please read the Prescribing Information.

Continue to List of benefits.

References: 1. American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines. Pediatrics. 1993;92:480–488. 2. Data available on request from Merck & Co., Inc., Professional Services—DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20702823(1)-CVX.

COMVAX is a registered trademark of Merck & Co., Inc.